Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis.

Alosaimy S, Sabagha NL, Lagnf AM, Zasowski EJ, Morrisette T, Jorgensen SCJ, Trinh TD, Mynatt RP, Rybak MJ.

Infect Dis Ther. 2020 Apr 4. doi: 10.1007/s40121-020-00292-8. [Epub ahead of print]

PMID:
32248513
2.

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections.

Alosaimy S, Jorgensen SCJ, Lagnf AM, Melvin S, Mynatt RP, Carlson TJ, Garey KW, Allen D, Venugopalan V, Veve M, Athans V, Saw S, Yost CN, Davis SL, Rybak MJ.

Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051. doi: 10.1093/ofid/ofaa051. eCollection 2020 Mar.

3.

Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study.

Jorgensen SCJ, Zasowski EJ, Trinh TD, Lagnf AM, Bhatia S, Sabagha N, Abdul-Mutakabbir JC, Alosaimy S, Mynatt RP, Davis SL, Rybak MJ.

Clin Infect Dis. 2019 Aug 12. pii: ciz746. doi: 10.1093/cid/ciz746. [Epub ahead of print]

PMID:
31404468
4.

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.

Claeys KC, Zasowski EJ, Trinh TD, Casapao AM, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):199-208. doi: 10.1007/s40121-019-0242-5. Epub 2019 Mar 27.

5.

Making the change to area under the curve-based vancomycin dosing.

Heil EL, Claeys KC, Mynatt RP, Hopkins TL, Brade K, Watt I, Rybak MJ, Pogue JM.

Am J Health Syst Pharm. 2018 Dec 15;75(24):1986-1995. doi: 10.2146/ajhp180034. Epub 2018 Oct 17. No abstract available.

PMID:
30333114
6.

Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient.

Jorgensen SCJ, McDonald P, Mynatt RP, Pogue JM, Lerner SA, Dhar S, Salimnia H, Rybak MJ.

J Antimicrob Chemother. 2018 Dec 1;73(12):3529-3531. doi: 10.1093/jac/dky346. No abstract available.

PMID:
30188993
7.

An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two Cities.

Pogue JM, Heil EL, Lephart P, Johnson JK, Mynatt RP, Salimnia H, Claeys KC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02538-17. doi: 10.1128/AAC.02538-17. Print 2018 May.

8.

Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, Rybak MJ.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01684-17. doi: 10.1128/AAC.01684-17. Print 2018 Jan.

9.

A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, Pogue JM, Rybak MJ.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01293-17. doi: 10.1128/AAC.01293-17. Print 2017 Dec.

10.

Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.

Navalkele B, Pogue JM, Karino S, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Koons J, Hussain T, Perry W, Evans R, Martin ET, Mynatt RP, Murray KP, Rybak MJ, Kaye KS.

Clin Infect Dis. 2017 Jan 15;64(2):116-123. doi: 10.1093/cid/ciw709. Epub 2016 Oct 20.

PMID:
27986669
11.

Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.

Karino S, Kaye KS, Navalkele B, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Martin ET, Mynatt RP, Murray KP, Rybak MJ, Pogue JM.

Antimicrob Agents Chemother. 2016 May 23;60(6):3743-50. doi: 10.1128/AAC.03011-15. Print 2016 Jun.

12.

Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury.

Faris J, Mynatt RP, Hall Snyder AD, Rybak MJ.

Infect Dis Ther. 2015 Dec;4(4):519-28. doi: 10.1007/s40121-015-0096-4. Epub 2015 Nov 5.

13.

The State of Antimicrobial Stewardship in Michigan: Results of a Statewide Survey on Antimicrobial Stewardship Efforts in Acute Care Hospitals.

Collins CD, Miller DE, Kenney RM, Mynatt RP, Tiberg MD, Cole K, Sutton JD, Pogue JM.

Hosp Pharm. 2015 Mar;50(3):180-4. doi: 10.1310/hpj5003-180. No abstract available.

14.

Nephrotoxicity comparison of two commercially available generic vancomycin products.

Sutton JD, Mynatt RP, Kaye KS, Murray KP, Rybak MJ, Pogue JM.

Antimicrob Agents Chemother. 2015 Sep;59(9):5470-4. doi: 10.1128/AAC.00388-15. Epub 2015 Jun 29.

15.

Implementation and outcomes of a pharmacy residency mentorship program.

Raub JN, Thurston TM, Fiorvento AD, Mynatt RP, Wilson SS.

Am J Health Syst Pharm. 2015 Jun 1;72(11 Suppl 1):S1-5. doi: 10.2146/ajhp140884.

PMID:
25991586
16.

Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.

Claeys KC, Smith JR, Casapao AM, Mynatt RP, Avery L, Shroff A, Yamamura D, Davis SL, Rybak MJ.

Antimicrob Agents Chemother. 2015 Apr;59(4):1969-76. doi: 10.1128/AAC.04141-14. Epub 2015 Jan 20.

17.

Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center.

Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS.

Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S388-93. doi: 10.1093/cid/ciu594.

PMID:
25371515
18.

Bringing the "power" to Cerner's PowerChart for antimicrobial stewardship.

Pogue JM, Potoski BA, Postelnick M, Mynatt RP, Trupiano DP, Eschenauer GA, Kaye KS.

Clin Infect Dis. 2014 Aug 1;59(3):416-24. doi: 10.1093/cid/ciu271. Epub 2014 Apr 18.

PMID:
24748518
19.

Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ.

Antimicrob Agents Chemother. 2014 May;58(5):2541-6. doi: 10.1128/AAC.02371-13. Epub 2014 Feb 18.

20.

Automated alerts coupled with antimicrobial stewardship intervention lead to decreases in length of stay in patients with gram-negative bacteremia.

Pogue JM, Mynatt RP, Marchaim D, Zhao JJ, Barr VO, Moshos J, Sunkara B, Chopra T, Chidurala S, Kaye KS.

Infect Control Hosp Epidemiol. 2014 Feb;35(2):132-8. doi: 10.1086/674849. Epub 2013 Dec 24.

PMID:
24442074
21.

Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10.

Pogue JM, Marchaim D, Abreu-Lanfranco O, Sunkara B, Mynatt RP, Zhao JJ, Bheemreddy S, Hayakawa K, Martin ET, Dhar S, Kaye KS, Lephart PR.

J Antibiot (Tokyo). 2013 Oct;66(10):625-7. doi: 10.1038/ja.2013.56. Epub 2013 May 29. No abstract available.

PMID:
23715037
22.

Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.

Marchaim D, Sunkara B, Lephart PR, Gudur UM, Bhargava A, Mynatt RP, Zhao JJ, Bheemreddy S, Hayakawa K, Chopra T, Dhar S, Kaye KS.

Infect Control Hosp Epidemiol. 2012 Aug;33(8):853-5. doi: 10.1086/666632. Epub 2012 Jun 11. No abstract available.

PMID:
22759556
23.

Moving antimicrobial stewardship from restriction to facilitation.

Martin CA, Armitstead JA, Mynatt RP, Hoven AD.

Am J Health Syst Pharm. 2011 Jan 15;68(2):109-10. doi: 10.2146/ajhp100272. No abstract available.

PMID:
21200053
24.

Peptic ulcer disease: clinically relevant causes and treatments.

Mynatt RP, Davis GA, Romanelli F.

Orthopedics. 2009 Feb;32(2):104.

PMID:
19301796

Supplemental Content

Loading ...
Support Center